A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT07728188. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Multiple myeloma (MM) is a plasma cell malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The disease primarily localizes to the bones and bone marrow, with resultant cytopenias, bone pain, fractures, infections, hypercalcemia, and renal failure. This study aims to evaluate the safety and change in disease activity of etentamig in combination with pomalidomide compared with standard available therapies in participants with relapsed or refractory multiple myeloma who have received 1-3 prior lines of treatment, including lenalidomide. Etentamig is an investigational drug being developed for the treatment of relapsed or refractory multiple myeloma. This is a randomized, open-label study. The study will include a safety run-in portion and a randomized portion. The safety run-in participants will receive etentamig in combination with pomalidomide. The randomized portion of the study participants will receive either etentamig with pomalidomide or Standard Available Therapies (SATs). Approximately 520 participants will be enrolled in the study at approximately 200 sites worldwide. Prior to initiation of the randomized portion of the study, the safety run-in will be conducted in which participants will receive etentamig injections plus oral pomalidomide. Following review of the safety run-in data and per protocol-defined criteria, the study will advance to the randomized portion where participants will be randomized to receive either etentamig injections plus oral pomalidomide or investigator's choice of SAT: SC daratumumab, oral pomalidomide, and oral/ IV dexamethasone (DPd); SC daratumumab, IV carfilzomib, and oral/IV dexamethasone (DKd); or SC teclistamab monotherapy. The total study duration is approximately 75 months There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Study identification
- NCT ID
- NCT07728188
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 520 participants
Conditions and interventions
Conditions
Interventions
- Etentamig Drug
- Pomalidomide Drug
- Daratumumab Drug
- Dexamethasone Drug
- Carfilzomib Drug
- Teclistamab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 29, 2026
- Primary completion
- Jan 31, 2033
- Completion
- Jan 31, 2033
- Last update posted
- Jul 26, 2026
2026 – 2033
United States locations
- U.S. sites
- 24
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center /ID# 285339 | Tucson | Arizona | 85704 | — |
| Toi Clinical Research - Whittier /ID# 284462 | Cerritos | California | 90703 | — |
| University of California Los Angeles /ID# 282444 | Los Angeles | California | 90095-3075 | — |
| University Of Colorado - Anschutz Medical Campus /ID# 283478 | Aurora | Colorado | 80045 | — |
| MedStar Georgetown University Hospital /ID# 283734 | Washington D.C. | District of Columbia | 20007 | — |
| Cleveland Clinic Florida /ID# 283692 | Weston | Florida | 33331 | — |
| Northwest Georgia Oncology Centers /ID# 284769 | Marietta | Georgia | 30060 | — |
| Rush University Medical Center /ID# 283095 | Chicago | Illinois | 60612 | — |
| Beth Israel Deaconess Medical Center /ID# 285204 | Boston | Massachusetts | 02215 | — |
| Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 282591 | Grand Rapids | Michigan | 49503 | — |
| The Mount Sinai Hospital /ID# 283535 | New York | New York | 10029 | — |
| Columbia University Medical Center /ID# 283510 | New York | New York | 10032 | — |
| Weill Cornell Medicine - Cornell University /ID# 283712 | New York | New York | 10065 | — |
| University of Rochester Medical Center /ID# 283480 | Rochester | New York | 14642 | — |
| University of North Carolina Lineberger Comprehensive Cancer Center /ID# 281454 | Chapel Hill | North Carolina | 27599 | — |
| Duke University Medical Center /ID# 283475 | Durham | North Carolina | 27710 | — |
| Novant Health Forsyth Medical Center /ID# 283485 | Winston-Salem | North Carolina | 27103 | — |
| University Hospitals Cleveland Medical Center /ID# 283527 | Cleveland | Ohio | 44106 | — |
| Oregon Health and Science University /ID# 282023 | Portland | Oregon | 97239 | — |
| SCRI Oncology Partners /ID# 281380 | Nashville | Tennessee | 37203 | — |
| MD Anderson Houston /ID# 282622 | Houston | Texas | 77030-4000 | — |
| Huntsman Cancer Institute /ID# 283512 | Salt Lake City | Utah | 84112 | — |
| VCU Massey Cancer Center: Dalton Oncology Clinic /ID# 283606 | Richmond | Virginia | 23298 | — |
| University of Wisconsin Hospitals and Clinics /ID# 282516 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07728188, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07728188 live on ClinicalTrials.gov.